Determination of chemoresistance of ovarian cancer cells in vitro-Reference-Cited by-同舟云学术

Determination of chemoresistance of ovarian cancer cells in vitro

Published:2019-12-15 Issue:4 Volume:6 Page:8-25
ISSN:2413-3787
Container-title:Advances in molecular oncology
language:
Short-container-title:Usp. mol. onkol

Author:

Kuzin K. A.¹^ORCID,Fetisov T. I.¹^ORCID,Knyazev R. I.²^ORCID,Fomina L. Ya.¹,Meheda L. V.¹,Lesovaya E. A.³^ORCID,Belitsky G. A.¹,Yakubovskaya M. G.¹^ORCID,Kirsanov K. I.⁴^ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia

3. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.P. Pavlov Ryazan State Medical University

4. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Peoples' Friendship University of Russia

Abstract

Objectives: to provide a rationale for existing approaches for the evaluation of chemoresistance of ovarian cancer in vitro, to perform a comparative analysis of the methods and to assess the perspectives of their further application.Materials and methods. For the review preparation, we analyzed articles on experimental testing of ovarian cancer resistance to chemotherapeutic agents, available at biomedical literature databases SciVerse Scopus (158), PubMed (323), Web of Science (285), RSCI (64). The review cited 37 recent publications, 12 of them being published over the past three years, and 16 articles being referred as pioneer publications on techniques previously and used today.Results. Peculiarities of the main methods for assessing the resistance and sensitivity of a cancer to various chemotherapeutic drugs using primary cultures of tumor cells obtained from biopsy or surgical material are analyzed. Proliferative and metabolic activities as well as the level of cell death were considered as the main evaluated characteristics of tumor cells. The methodological features of the described methods are discussed, as well as the prospects for their further application.Conclusion. Predictive detection of chemoresistance of ovarian cancer is based on testing the viability of tumor cells in the presence of a chemotherapeutic drug. The results of studies of the key mechanisms of chemoresistance development in tumor cells provide the rationale for improving in vitro testing.

Publisher

Publishing House ABV Press

Subject

Cancer Research,Biochemistry, medical,Genetics(clinical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference37 articles.

1. State of oncological care in Russia in 2018. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2019. 236 p. (In Russ.).

2. Tyulyandin S.A., Kolomiets L.A., Morkhov K.Yu. et al. Practical guidelines on drug treatment of ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Malignant tumors: RUSSCO practical guidelines, 2018;8:145–55. (In Russ.).

3. Markman M., Rothman R., Hakes T. et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9(3):389–93. DOI: 10.1200/JCO.1991.9.3.389.

4. Van Zyl B., Tang D., Bowden N.A. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocr Relat Cancer 2018;25(5):303–18. DOI: 10.1530/ERC17-0336.

5. Belitsky G.A., Kirsanov K.I., Lesovaya E.A., Yakubovskaya M.G. Prevention of therapy-related malignances in cancer survivors. Oncotarget 2019;10(22):2114–5. DOI: 10.18632/oncotarget.26781.